Promising drug trial offers hope for teens with tough bone cancers
NCT ID NCT05395741
First seen May 07, 2026 · Last updated May 08, 2026 · Updated 1 time
Summary
This study tests a drug called regorafenib in 30 patients aged 9 to 21 with bone cancers (osteosarcoma or Ewing sarcoma) that have not responded to standard therapy. The goal is to see if the drug can help control the disease and improve survival, while also checking its safety. The approach combines advanced diagnostics to tailor treatment for each patient.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OSTEOSARCOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Maria Sklodowska-Curie National Research Institute of Oncology
Warsaw, 02-781, Poland
-
the Institute of Mother and Child
Warsaw, 01-211, Poland
Conditions
Explore the condition pages connected to this study.